CA3070538A1 - Compositions containing cannabinoid analog conjugates and methods of use - Google Patents

Compositions containing cannabinoid analog conjugates and methods of use Download PDF

Info

Publication number
CA3070538A1
CA3070538A1 CA3070538A CA3070538A CA3070538A1 CA 3070538 A1 CA3070538 A1 CA 3070538A1 CA 3070538 A CA3070538 A CA 3070538A CA 3070538 A CA3070538 A CA 3070538A CA 3070538 A1 CA3070538 A1 CA 3070538A1
Authority
CA
Canada
Prior art keywords
composition
cannabinoid
chelator
analog
medical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3070538A
Other languages
English (en)
French (fr)
Inventor
Jerry L. Bryant, Jr.
David J. Yang
Jana Rauvolfova
Tori STRONG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vyripharm Enterprises LLC
Original Assignee
Vyripharm Enterprises LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vyripharm Enterprises LLC filed Critical Vyripharm Enterprises LLC
Publication of CA3070538A1 publication Critical patent/CA3070538A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/0412—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K51/0421—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nuclear Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3070538A 2017-07-18 2018-07-18 Compositions containing cannabinoid analog conjugates and methods of use Pending CA3070538A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762533894P 2017-07-18 2017-07-18
US62/533,894 2017-07-18
PCT/US2018/042707 WO2019018536A1 (en) 2017-07-18 2018-07-18 COMPOSITIONS CONTAINING CONJUGATES OF CANNABINOID ANALOGUES AND METHODS OF USE THEREOF

Publications (1)

Publication Number Publication Date
CA3070538A1 true CA3070538A1 (en) 2019-01-24

Family

ID=65016693

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3070538A Pending CA3070538A1 (en) 2017-07-18 2018-07-18 Compositions containing cannabinoid analog conjugates and methods of use

Country Status (10)

Country Link
EP (1) EP3654971A4 (de)
JP (1) JP2020527589A (de)
KR (1) KR20200031663A (de)
CN (1) CN111065391A (de)
AU (1) AU2018302155B2 (de)
CA (1) CA3070538A1 (de)
EA (1) EA202090116A1 (de)
IL (1) IL272060A (de)
MX (1) MX2020000673A (de)
WO (1) WO2019018536A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3145109A1 (en) * 2019-06-24 2020-12-30 Diverse Biotech, Inc. Cannabinoid conjugate molecules
AU2020366257A1 (en) 2019-10-15 2022-06-02 Diverse Biotech, Inc. Conjugate molecules
CN112807301A (zh) * 2020-12-30 2021-05-18 福建省中科生物股份有限公司 麻类植物提取化合物Cannabiorcol在制备抗肿瘤药物上的用途
US11554184B2 (en) 2021-03-26 2023-01-17 Vyripharm Enterprises, Inc. Synthetic cannabinoid combination therapy compositions and methods for personalized and targeted therapies including the treatment of infectious diseases
US20220305148A1 (en) * 2021-03-26 2022-09-29 Vyripharm Enterprises, Inc. Natural cannabinoid combination therapy compositions and methods for personalized and targeted therapies including the treatment of infectious diseases
US20220305145A1 (en) * 2021-03-26 2022-09-29 Vyripharm Enterprises, Inc. Compositions and methods for diagnosing viral infections including covid-19 and for infection severity monitoring as well as targeted detection of cytokine storm

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754188B2 (en) * 2003-06-30 2010-07-13 Merck Sharp & Dohme Corp. Radiolabeled cannabinoid-1 receptor modulators
KR101653182B1 (ko) * 2006-04-19 2016-09-01 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 세포 영상화 및 치료를 위한 조성물 및 방법
US8367714B2 (en) * 2007-08-28 2013-02-05 Vanderbilt University Cannabinoid receptor targeted agent
US20120288442A1 (en) * 2011-05-11 2012-11-15 Atomic Energy Council-Institute Of Nuclear Energy Research Nuclear Imaging Method Using Molecular Target Detection Agent for Liver Fibrosis
EP2992880A1 (de) * 2014-09-04 2016-03-09 Fundació Institut de Recerca de l'Hospital de la Santa Creu l Sant Pau Verwendung von Hämoxygenase-1-Induktoren und Cannabinoid-2-Rezeptor oder Delta-Opiod-Rezeptoragonisten bei Entzündungsschmerz
GB201417067D0 (en) * 2014-09-26 2014-11-12 South African Nuclear Energy Radiopharmaceutical conjugate

Also Published As

Publication number Publication date
IL272060A (en) 2020-03-31
CN111065391A (zh) 2020-04-24
AU2018302155B2 (en) 2022-09-15
WO2019018536A1 (en) 2019-01-24
EA202090116A1 (ru) 2020-05-14
MX2020000673A (es) 2020-07-29
EP3654971A1 (de) 2020-05-27
JP2020527589A (ja) 2020-09-10
AU2018302155A1 (en) 2020-02-06
EP3654971A4 (de) 2021-04-21
KR20200031663A (ko) 2020-03-24

Similar Documents

Publication Publication Date Title
AU2018302155B2 (en) Compositions containing cannabinoid analog conjugates and methods of use
Muller Folate based radiopharmaceuticals for imaging and therapy of cancer and inflammation
CA2967254C (en) Contrast agents for applications including imaging cancer
KR102017324B1 (ko) 신규한 asm 활성 직접 억제 화합물 2-아미노-2-(1,2,3-트리아졸-4-일)프로판-1,3-디올 유도체 및 이의 용도
KR20030031905A (ko) 에틸렌디시스테인(ｅｃ)-약물 접합체
Kawamura et al. Synthesis and evaluation of [11 C] XR9576 to assess the function of drug efflux transporters using PET
CA3171183A1 (en) Fap-targeted radiopharmaceuticals and imaging agents, and uses related thereto
Serdons et al. Synthesis and evaluation of a 99mTc-BAT-phenylbenzothiazole conjugate as a potential in vivo tracer for visualization of amyloid β
US7141234B1 (en) Imaging of drug accumulation as a guide to antitumor therapy
WO2016040458A2 (en) Pet probes of radiofluorinated carboximidamides for ido-targeted imaging
Liolios et al. Synthesis, characterization and evaluation of 68Ga labelled monomeric and dimeric quinazoline derivatives of the HBED-CC chelator targeting the epidermal growth factor receptor
Solingapuram Sai et al. Initial biological evaluations of 18 F-KS1, a novel ascorbate derivative to image oxidative stress in cancer
Li et al. 99mTc-cyclopentadienyl tricarbonyl chelate-labeled compounds as selective sigma-2 receptor ligands for tumor imaging
AU2017283151A1 (en) Modified dextran conjugates comprising a lysine-urea-glutamate pharmacophore
Kwon et al. Novel multifunctional 18F-labelled PET tracer with prostate-specific membrane antigen-targeting and hypoxia-sensitive moieties
Zhang et al. Discovery and development of brain-penetrant 18F-labeled radioligands for neuroimaging of the sigma-2 receptors
Mahmoud et al. Radioiodination and in vivo assessment of the potential of newly synthesized pyrrolizine-5-carboxamides derivative in tumor model
Tian et al. Synthesis and evaluation of new 1-oxa-8-azaspiro [4.5] decane derivatives as candidate radioligands for sigma-1 receptors
JP2022501383A (ja) シールド剤およびそれらの使用
US7687538B2 (en) Agents with selective κ-opioid receptor affinity
Bolzati et al. Avidin–biotin system: a small library of cysteine biotinylated derivatives designed for the [99mTc (N)(PNP)] 2+ metal fragment
Shaghaghi et al. Current development of sigma-2 receptor radioligands as potential tumor imaging agents
JP7264489B2 (ja) イメージング及び放射線療法のための放射標識された蛍光性ｐａｒｐ阻害剤
Mardanshahi et al. Synthesis and evaluation of 99mTc-labeled 1-(2-Pyridyl) piperazine derivatives as radioligands for 5HT7 receptors
US20200164075A1 (en) Small molecule inhibitors for early diagnosis of prostate specific membrane antigen cancers and neurodegenerative diseases